Altamira Therapeutics Ltd.
CYTOF · OTCMCIK 1601936fmd_1452KFG617Q86NEDHP81JKF6CBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2025, 18 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 0 | 0 |
| Cost of revenue | – | – | – | – | – | – | 2 | 1 | 0 |
| Gross profit | – | – | – | – | – | – | (2) | (1) | (0) |
| Research and development | 27 | 25 | 19 | 7 | 3 | 3 | 3 | 15 | 3 |
| Selling, general and administrative | – | – | – | – | – | 3 | 4 | 3 | 3 |
| Operating income | (31) | (30) | (24) | (11) | (7) | (5) | (7) | (18) | (6) |
| Interest expense | 1 | 2 | 4 | 2 | 2 | 6 | 2 | 2 | 1 |
| Income before taxes | (30) | (31) | (24) | (11) | (7) | (8) | (7) | (19) | (7) |
| Income tax expense | 0 | (0) | (0) | 0 | (0) | (0) | (0) | (0) | – |
| Net income from continuing operations | (30) | (31) | (24) | (11) | (7) | (8) | (7) | (19) | (7) |
| Net income | (30) | (31) | (24) | (11) | (7) | (8) | (17) | (27) | (4) |